Aarti Pharmalabs up 10.3% as AGM deck targets 15-18% CAGR, outweighing weak FY26

The AGM presentation (page 7) lays out a soft FY26 on a consolidated basis:

• Operational revenue of INR 18,194 million in FY26 versus INR 21,151 million in FY25, a (14.0)% year‑on‑year decline.
• EBITDA of INR 4,024 million against INR 4,644 million, down (13.4)%.
• PAT of INR 1,747 million versus INR 2,724 million, a (35.9)% drop.

The filing explicitly notes that recognition of fair value movement on a long‑dated USD forward contract under FVTPL impacted reported profitability, with previous year figures restated. It also flags that from 1 April 2025, Ganesh Polychem Limited is treated as a joint venture and consolidated using the equity method, making current‑period consolidated numbers not directly comparable with FY25.

Ordinarily, such headline declines might weigh on the stock. However, the live market read points to investors latching on to the company’s growth narrative and previously disclosed strong Q1 FY27 performance, which the AGM deck appears to have reinforced rather than contradicted.

According to the market commentary, the rally is being linked to a renewed focus on Aarti Pharmalabs’ first‑quarter performance for FY27, which had been announced earlier and highlighted:

• Year‑on‑year profit growth of 65.4% in that quarter.
• Revenue growth of 38.7% year‑on‑year.

Those Q1 FY27 figures do not appear in the AGM presentation itself, but the presentation’s emphasis on capacity additions, CDMO/CMO positioning and medium‑term growth targets appears to have reminded investors of that strong start to the new fiscal year. The stock’s 10.3% move after the filing suggests the AGM communication was a key catalyst.

On the standalone side, the deck (page 6) presents multi‑year trends:

• Standalone operational revenue of INR 17,976 million in FY26 versus INR 17,714 million in FY25, up 1.5%.
• Standalone EBITDA of INR 4,061 million versus INR 4,265 million, down (4.8)%, with EBITDA margin at 22.59% versus 24.08% (a (149) bps contraction).
• Standalone PAT of INR 1,762 million versus INR 2,573 million, down (31.5)%, with PAT margin at 9.80% versus 14.53% (a (473) bps decline).
• Diluted EPS of INR 19.42 versus INR 28.38, down (31.6)%.

These numbers underline that FY26 was a consolidation year, with margin pressure and higher depreciation and finance costs (up 31.9% and 83.2% year‑on‑year respectively on the standalone P&L).

Yet, the same slide deck also shows a longer‑term growth arc (page 6): standalone operational revenue rising from INR 1,511 crore in FY23 to INR 1,798 crore in FY26, and EBITDA moving from INR 308 crore to INR 406 crore over that period, even after the latest dip.

A major reason the market appears willing to look through the FY26 earnings dip is the scale and direction of ongoing capex, detailed on page 8:

Atali greenfield project (Gujarat)

• Estimated investment of INR 400 crores.
• Initial capacity of around 450 KL (Block 1).
• Land bank of 80 acres.
• Timeline: about 80% of this capacity targeted to be operational by Q4FY26.
• Product focus: intermediates and CDMO/CMO.
• Future potential: the Atali site is described as scalable up to 8–10x of Phase 1 capacity.

Tarapur brownfield expansion (Maharashtra)

• Estimated investment of INR 210 crores.
• Proposed capacity of 9,000 MTPA, with current utilisation at 6,000 MTPA.
• Timeline: operationalised in Q1FY27.
• Product focus: Xanthine derivatives.

The strategic rationale section highlights long‑standing beverage‑sector relationships and an ambition to increase wallet share with beverage customers and in pharmaceutical‑grade Xanthine derivatives.

For equity markets, these details matter because they tie directly into future revenue and margin potential, especially in higher‑value CDMO/CMO work and specialty Xanthines.

The most explicit forward‑looking signal comes on page 9, where management states it is targeting 15–18% revenue and EBITDA CAGR over the next 3–4 years. The same slide notes:

• FY26 capex reached approximately INR 400 cr, with FY27 capex expected at similar levels.
• Initiation of R&D investment in FY27 towards TIDES (Peptides & Oligonucleotides) to expand portfolio capabilities.
• Announced capex for Atali Block 2 for specific CDMO/CMO projects, with groundbreaking planned in Q3FY27.

This combination of sustained capex, entry into TIDES and explicit multi‑year growth targets appears to be what investors are rewarding, particularly when set against the strong Q1 FY27 base the market commentary references.

The AGM presentation does not provide quarter‑wise FY27 numbers, nor does it quantify order book, pricing trends or customer concentration. It also does not break out segment‑wise margins beyond the consolidated and standalone P&L views.

As a result, while the 10.3% intraday jump to Rs 934 appears closely tied to the AGM communication and the reminder of robust Q1 FY27 performance, some of the optimism reflects market interpretation of the capex and guidance rather than new hard data on FY27 earnings within this specific filing.

For now, the message from the tape is clear: investors are looking past a difficult FY26 and trading Aarti Pharmalabs more on its capacity build‑out, CDMO positioning and stated 15–18% CAGR ambition than on last year’s compressed profitability.